Vical Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,718.00
15,217.00
20,950.00
14,531.00
13,819.00
1,622
Cost of Goods Sold (COGS) incl. D&A
12,198.00
10,824.00
11,127.00
6,291.00
6,479.00
701
Gross Income
4,480.00
4,393.00
9,823.00
8,240.00
7,340.00
921
SG&A Expense
23,968.00
20,669.00
19,227.00
17,417.00
20,726.00
17,303
EBIT
28,448.00
16,276.00
9,404.00
-
13,386.00
16,382
Unusual Expense
2,904.00
350.00
-
-
-
3,264
Non Operating Income/Expense
-
134.00
166.00
-
-
2,300
Pretax Income
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
Consolidated Net Income
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
Net Income
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
Net Income After Extraordinaries
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
Net Income Available to Common
31,238.00
16,492.00
9,238.00
8,973.00
12,960.00
16,254
EPS (Basic)
3.60
1.86
1.00
0.90
1.01
0.74
Basic Shares Outstanding
8,684.00
8,878.60
9,175.10
10,019.00
12,888.00
21,842
EPS (Diluted)
3.60
1.86
1.01
0.90
1.01
0.74
Diluted Shares Outstanding
8,684.00
8,878.60
9,175.10
10,019.00
12,888.00
21,842
EBITDA
26,235.00
14,613.00
8,245.00
8,060.00
12,593.00
16,182
Non-Operating Interest Income
114.00
-
-
204.00
426.00
1,092

About Vical

View Profile
Address
10390 Pacific Center Court
San Diego California 92121
United States
Employees -
Website http://www.vical.com
Updated 07/08/2019
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E.